Breast Cancer Clinical Trial
Official title:
Use of PECS Block in Partial Mastectomy for Postoperative Pain Control and Mitigation of Narcotic Use- A Randomized Control Trial
The aim of this study is to evaluate patients who are undergoing partial mastectomy or
removal of breast tissue and see if a pectoralis nerve block (PECS) can provide a meaningful
improvement in postoperative pain control over standard pain medication. The hope is that
this will decrease the need for postoperative narcotics. Prior studies have shown improved
pain control using a PECS block in patients who undergo a mastectomy. PECS block is a
procedure in which local anesthesia, similar to that used by dentists, is injected in the
muscles of your chest and arm pit during your surgical procedure while you are asleep. This
anesthetizes the nerves in the area which decreases pain. The local anesthetic used is called
Marcaine. Marcaine is the brand name for bupivacaine hydrochloride which is an anesthetic
known for its long duration in comparison to lidocaine.
It is known that postoperative pain is a risk factor for chronic pain which is tied to
increased narcotic use. Due to the opioid epidemic considerable time and research has gone
into decreasing opioid use particularly in post-operative period. The PECS block procedure
involves injecting local anesthesia between two chest muscles called pectoralis major and
pectoralis minor. There is an additional injection between the pectoralis minor and serratus
anterior which is another muscle of the chest.
This study will be conducted at Lankenau Medical Center of Main Line Health. You have been
selected since you will be undergoing a partial mastectomy (removal of a part of your
breast). It is believed that PECS block has the potential to benefit your postoperative pain
control. A total of 130 patients will be recruited and 65 will be placed into the treatment
arm (receive intraoperative nerve block) and 65 will be placed into the non- treatment arm
(no nerve block) for comparison.
Prior investigations have shown that use of intraoperative PECS blocks in patients undergoing
a Modified Radical Mastectomy improves postoperative pain control and decreases postoperative
narcotic use which will eventually mitigate the issue of dependence on narcotics
postoperatively (Kulhari et al, Blanco et al). The aim of this study is to do a prospective
randomized control of patients undergoing a Partial Mastectomy at Lankenau Medical Center to
see if pectoral nerve block (PECS) provides a meaningful improvement in postoperative pain
control over standard pain medication as well as a decrease in postoperative narcotic use.
PECS block as described by Blanco et al has been used safely and effectively used for
modified radical mastectomy in multiple studies as reviewed above (Blanco et al, Kumar et al,
Kulhari et al). The breast surgeons at Lankenau Medical Center within Main Line Health are
currently using the PECS block as part of their partial mastectomy procedure and have been
since 5/1/19. The PECS block is currently being used at random when time and resources allow
There are not certain subsets or patients who are selected for this procedure. This procedure
has been well tolerated by patients and has proved feasible for the surgeons and surgical
team to facilitate. Therefore since PECS block for partial mastectomy are within the standard
of care at Lankenau Medical Center this study only introduces a risk of randomization rather
than the increased risk of the procedure itself.
This is a randomized prospective control study looking at patients at Lankenau Hospital
undergoing partial mastectomy from 8/30/19- 8/30/20 after obtaining Institutional Review
Board (IRB) approval. The plan is to recruit 130 patients with 65 patients randomized into
each cohort. One cohort will receive the PECS II block intraoperatively and one cohort will
not. This will be a single blinded randomized control trial in that the surgeon knows who
will be receiving the block however the patient will be blinded. Patient must be able to
provide their own consent to be included in this study. There will be no advertisement or
compensation for this study. The study will be explained to the eligible candidates at time
of discussion of their surgery. Patients will be informed that involvement in the study does
not affect their ability to seek or receive care at this facility.
A written informed consent will be obtained from all patients. The patients once scheduled
for surgery unit will be enrolled in research study by an independent research assistant. The
participants will be allocated randomly into two groups according to block randomization
schedule shown below. Group one will receive anesthesia only and Group two will receive
anesthesia and PECS block. The surgeon who will be performing the intraoperative block will
be informed of the random and independent assignment prior to surgery. The patients will be
instructed on usage of a 10-mm Visual Analogue Scale (VAS) for pain graded from 0 (no pain)
to 10 (most severe pain) before surgery. Patients will be blinded as to whether or not they
will be receiving intraoperative PECS block. In both the control and test groups, patients
will receive general anesthesia with laryngeal mask airway or endotracheal tube per
anesthesiologist discretion. Induction of anesthesia will use fentanyl 1 μg/kg and propofol
1.5-2 mg/kg until loss of verbal response with or without muscle relaxant as needed.
Maintenance of anesthesia will be assessed for any intraoperative rise in heart rate and
systolic blood pressure more than 20% from pre-induction value. If this occurs fentanyl 0.25
μg/kg can be administered IV. Toradol should be given unless contraindication at the end of
the case. No ketamine or dilaudid will be used. Long acting opioids will be avoided. Once
anesthesia is instituted prior to prepping and draping a timeout will be called during which
patient will be identified and procedures to be performed will be identified.
Procedures The patient will be kept in supine position with ipsilateral arm in abducted
position. The skin overlying the ipsilateral breast and adjoining infraclavicular and
axillary regions will be disinfected with chloraprep and sterile draping of the area is
performed. A linear ultrasound probe of high frequency (6-13 MHz) of a portable ultrasound
system (Sonosite, Micromaxx Bothell, Washington USA) is taken. The probe will be covered with
a sterile transparent dressing and a sterile conductivity gel will be applied. The imaging
depth on the ultrasound screen is set to 4-6 cm. The ultrasound probe will first be placed
cephalocaudally in the infraclavicular region and moved laterally to locate vessels directly
above the 1st rib. With further lateral and downward movements the 3rd and 4th ribs will be
identified. The probe is maneuvered and appropriate anatomical structures including
pectoralis major and minor muscles and serratus anterior muscle are identified.
The interface between pectoralis major, pectoralis minor and serratus anterior are
identified. A spinal needle 20 gauge and 4 inches in length will be used to instill 10 cc of
0.2% Marcaine between serratus anterior and pectoralis minor. Aspiration is continuously used
to confirm that there is no intravenous or intra-arterial injection of local anesthesia. The
needle will then be withdrawn slightly, and 10 cc of 0.25% Marcaine is injected between
pectoralis major and pectoralis minor under direct ultrasound visualization. Attention is
then turned to the axilla of the operative side. A spinal needle under direct visualization
is used to deliver 10 cc of 0.25% Marcaine between latissimus dorsi and serratus anterior.
The PECS block is finished, and the rest of the procedure is performed according to surgeon
discretion. All patients whether or not they receive the PECS block will receive 10 cc of
0.25% Marcaine subcutaneously at incision site.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |